Iambic Therapeutics shares soar 16% in trading debut after $150M IPO

Iambic Therapeutics: Iambic Therapeutics is a San Diego-based clinical-stage biotechnology company that develops cancer treatments using an AI-driven drug discovery platform combining machine learning models with automated robotic labs. The firm focuses on small-molecule therapies for solid tumors and has established partnerships with major pharmaceutical companies. It recently transitioned to public markets through its Nasdaq listing following its initial public offering. AI Drug Discovery: Biotech companies employing AI to accelerate research are attracting significant investor and industry attention as part of efforts to improve drug development efficiency. Biotech IPO Activity: Young AI-focused biotechs continue to access public markets amid broader interest in the sector's potential despite challenging overall IPO conditions. Pharma Collaborations: Iambic has secured partnerships with established drugmakers including AbbVie and Takeda to advance its AI-enabled discovery programs in oncology and related areas.